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Abstract—Cardiac stem cells and early committed cells (CSCs-ECCs) express c-Met and insulin-like growth factor-1
(IGF-1) receptors and synthesize and secrete the corresponding ligands, hepatocyte growth factor (HGF) and IGF-1.
HGF mobilizes CSCs-ECCs and IGF-1 promotes their survival and proliferation. Therefore, HGF and IGF-1 were
injected in the hearts of infarcted mice to favor, respectively, the translocation of CSCs-ECCs from the surrounding
myocardium to the dead tissue and the viability and growth of these cells within the damaged area. To facilitate
migration and homing of CSCs-ECCs to the infarct, a growth factor gradient was introduced between the site of storage
of primitive cells in the atria and the region bordering the infarct. The newly-formed myocardium contained arterioles,
capillaries, and functionally competent myocytes that with time increased in size, improving ventricular performance at
healing and long thereafter. The volume of regenerated myocytes was 2200 m3 at 16 days after treatment and reached
5100 m3 at 4 months. In this interval, nearly 20% of myocytes reached the adult phenotype, varying in size from 10 000
to 20 000 m3. Moreover, there were 4313 arterioles and 15548 capillaries/mm2 myocardium at 16 days, and 316
arterioles and 39056 capillaries at 4 months. Myocardial regeneration induced increased survival and rescued animals
with infarcts that were up to 86% of the ventricle, which are commonly fatal. In conclusion, the heart has an endogenous
reserve of CSCs-ECCs that can be activated to reconstitute dead myocardium and recover cardiac function. (Circ Res.
2005;97:663-673.)
Key Words: cardiac progenitor cells  myocardial regeneration  mortality
Adult cardiac stem cells (CSCs) and early committed cells(ECCs) express the stem cell antigens c-kit, MDR1, and
Sca-1.1–4 c-kitPOS cells are self-renewing, clonogenic, and
multipotent and give rise to myocytes, smooth muscle cells
(SMCs), and endothelial cells (ECs) in vitro and in vivo.1,5 A
similar category of CSCs-ECCs has been found in the human
heart,6,7 suggesting that these undifferentiated cells partici-
pate in the normal turnover of cardiac cells and, under
favorable conditions, have the ability to form myocytes,
coronary arterioles, and capillary structures.1,5,7 The presence
of CSCs-ECCs raises the question of why they fail to respond
to ischemic injury with regeneration of myocytes and coro-
nary vessels and restoration of function. CSCs-ECCs distrib-
uted within the damaged area may die together with paren-
chymal cells, however, and SMCs and ECs in coronary
vessels prevent myocardial repair. For this reason, we have
explored the possibility that CSCs-ECCs, if properly acti-
vated, can translocate to sites of damage, survive the unfa-
vorable environment, multiply, and differentiate, forming
functionally competent myocardium.
Hepatocyte growth factor (HGF) stimulates cell migration8
by expression of metalloproteinases (MMPs)9 that by break-
ing down the extracellular matrix favor cell locomotion,
homing, and tissue reconstitution. The receptor of HGF,
c-Met, is expressed in bone marrow progenitor cells, satellite
cells, and embryonic myocytes.10,11 Insulin-like growth
factor-1 (IGF-1) is mitogenic, antiapoptotic, and necessary
for neural stem cell growth.12 IGF-1 promotes myocyte
formation and attenuates myocyte death after infarction.13
Together, these findings prompted us to determine whether
CSCs-ECCs express c-Met and whether HGF stimulates their
migration to the infarcted myocardium. If CSCs-ECCs ex-
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press IGF-1 receptor, IGF-1 may protect their viability and
enhance their growth within the infarct. Thus, myocardial
infarction was produced in mice and HGF and/or IGF-1 were
locally injected to trigger migration and homing of CSCs-
ECCs to the ischemic area. The impact of this intervention on
myocardial regeneration, heart function, and animal survival
was determined acutely, at healing and long thereafter to
evaluate its therapeutic efficacy.
Materials and Methods
Mice were infarcted, treated with IGF-1 and HGF (GFs) and
euthanized at different intervals up to 4 months. Myocardial regen-
eration was determined by confocal microscopy. An expanded
Materials and Methods can be found in an online-only data supple-
ment available at http://circres.ahajournals.org.
Results
CSCs
CSCs did not express markers of cardiac and hemopoietic cell
lineages.1 They were more numerous in the atria and apex
than in the ventricle (supplemental Figure S1). ECCs ex-
pressed transcription factors of cardiac (GATA-4) and myo-
cyte (MEF2C) lineages, identifying progenitor cells (Figure
1A through 1D). Also, c-kitPOS , MDR1POS, and Sca-1POS cells
expressed -sarcomeric actin or cardiac myosin, representing
myocyte precursors. SMC progenitors and precursors ex-
pressed GATA-6 and -smooth muscle actin and EC progen-
itors and precursors Ets-1 and von Willebrand factor, respec-
tively (supplemental Figure S2).
c-Met and IGF-1R
Most CSCs-ECCs expressed c-Met and IGF-1 receptor to-
gether with HGF and IGF-1 (supplemental Figure S3).
Migration studies documented that HGF had a chemoattrac-
tive effect on CSCs-ECCs that peaked at 100 ng/mL. Invasion
assays showed that 100 ng/mL HGF increased by 7-fold the
number of CSCs-ECCs that accumulated in the lower well of
a modified Boyden chamber. IGF-1 had few motogenic and
invasive properties (supplemental Figure S4). After HGF
Figure 1. Atrial clusters of CSCs-ECCs. c-kitPOS (A and B, green; arrowheads) and MDR1POS (C and D, magenta; arrowheads) cells in
normal hearts express GATA-4 (A and B; yellow) and MEF2C (C and D, white) in nuclei. Fibronectin (B and D, yellow) and myocytes (B
and D, -sarcomeric actin; red) are shown. *c-kitPOS (A and B) or MDR1POS (C and D) only. Double arrows indicate small-GATA-4POS
myocytes (B). E, HGF-IGF-1 and CSCs-ECCs. Gelatinase-activity appears as clear bands against blue background (upper panels).
MMP-2 and MMP-9 -protein is also shown (lower-panels). F, HGF and IGF-1 mRNA is enhanced in CSCs-ECCs of GF-treated infarcted
hearts. NC indicates negative control. HGF-protein in CSCs-ECCs of GF-treated infarcted hearts increased 3-fold, 3-fold, and 5-fold at
12 , 24, and 72 hours, respectively, whereas IGF-1 protein increased 2-fold, 4-fold, and 5-fold. HGF and IGF-1 formed by CSCs-ECCs
increased with time (ELISA; lower panels). ND indicates not detectable. *P0.05, ** P0.01 versus 30 and 60 minutes.
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administration, CSCs-ECCs had gelatinolytic activity and
secreted MMP-2 and MMP-9; IGF-1 had little effects on
MMPs (Figure 1E).
IGF-1 and HGF decreased apoptosis of CSCs-ECCs in
serum-free medium by 94% and 58%, respectively. More-
over, BrdUPOS CSCs-ECCs increased 11-fold with IGF-1 and
3-fold with HGF. The effects of both GFs on cell death and
growth were not different from those of IGF-1 alone (sup-
plemental Figure S5). Murine mRNA and protein for IGF-1
and HGF were present in non-stimulated CSCs-ECCs and
increased in GF-treated infarcted-hearts (Figure 1H). Animals
were injected with heterologous proteins, human IGF-1, and
HGF.
HGF and IGF-1 in the supernatant of GF-stimulated
CSCs-ECCs in serum-free medium increased from 30 min-
utes to 120 minutes, reaching a 13-fold and 26-fold elevation
at 120 minutes, respectively (Figure 1F). The increase in
murine HGF and IGF-1 mRNA, together with the significant
accumulation of murine HGF and IGF-1 protein in stimulated
CSCs-ECCs in vivo, supports the notion that CSCs-ECCs can
synthesize these GFs. The time-dependent increase in the
secretion of HGF and IGF-1 in vitro strengthens this conclu-
sion. Thus, CSCs-ECCs possess the c-Met-HGF and IGF-1
receptor-IGF-1 systems that promote cell growth and migra-
tion, attenuate apoptosis, and increase the secretion of their
ligands.
Migration of CSCs-ECCs
Because cycling CSCs-ECCs were identified in the atrioven-
tricular (AV) groove (supplemental Figures S6 and S7), a
retrovirus expressing enhanced green fluorescence protein
(EGFP)1,5 was injected in this region to label replicating cells
before the administration of the GFs. Integration and accu-
mulation of EGFP in the tagged cells required 48 hours
(supplemental Figure S8). Therefore, coronary occlusion was
performed 2 days after viral inoculation, and HGF and/or
IGF-1 were injected 5 hours later (supplemental Figure S9).
Increasing doses of HGF were used between the AV groove
and the infarct to favor migration of CSCs-ECCs to the
infarct. Fluorescein-conjugated HGF was injected to establish
its distribution; fluorescence intensity was higher adjacent to
the infarct than in the distant myocardium (Figure 2A through
2C). As shown by ELISA, HGF quantity was also higher in
the border than in the remote tissue (Figure 2D). Autocata-
lytic phosphorylation of c-Met and IGF-1R, phospho-Akt,
phospho-IRS-1, and phospho-FAK in c-kitPOS CSCs-ECCs
showed that these indices of c-Met and IGF-1 receptor
activation were barely detectable in untreated hearts. Con-
versely, their expression in CSCs-ECCs from GF-treated
infarcts increased with time (Figure 2E). Phospho-FAK and
phospho-c-Met were also detected by immunocytochemistry
(data not shown) and fluorescent-activated cell sorter (Figure
2F). Antibody specificity was determined by fluorescent-ac-
tivated cell sorter, and immunoprecipitation Western blotting
of Lewis lung carcinoma cells (Figure 2G and 2H).
The effects of GFs on cell migration were evaluated ex
vivo. Microscopic fields were analyzed for 1 to 5 hours to
measure movement of EGFPPOS cells (Figure 3A through 3E).
The same EGFPPOS cells were then characterized after fixa-
tion: EGFPPOS cells expressed antigens typical of CSCs-ECCs
(Figure 3F and 3G; supplemental Figure S10). EGFPPOS cells,
which were not CSCs-ECCs, were occasionally seen in the
AV groove; these cells did not move after GF administration.
EGFPPOS CSCs-ECCs migrated at 70 m/h (supplemental
Figure S11) from the AV groove to the border and central
infarct in 2 to 3 and 6 to 7 hours, respectively. IGF-1 had
minimal effect on locomotion. In GF-treated infarcts, the
number of EGFPPOS CSCs-ECCs and EGFPPOS-EGFPNEG
CSCs-ECCs in this region increased 3-fold and 8-fold,
respectively (supplemental Figure S12). Most CSCs-ECCs
expressed both c-Met and IGF-1 receptor and were commit-
ted to cardiac lineages (supplemental Figure S13 and S14).
Destiny of CSCs-ECCs
CSCs-ECCs can migrate via the coronary bed, the intersti-
tium, or both. Therefore, the coronary circulation was per-
fused with rhodamine-labeled dextran, and GFs were admin-
istrated at the time of observation. The coronary vasculature
was recognized by red fluorescence and EGFPPOS cells by
green fluorescence (Figure 4A through 4D; supplemental
Figure S15). In all cases, EGFPPOS cells were located outside
the vessels, suggesting that the coronary circulation was not
implicated in cell migration; EGFPPOS cells were found in
interstitial tunnels defined by fibronectin (Figure 4E).
The death, survival, and growth of CSCs-ECCs within the
infarct was characterized (supplemental Figures S16 through
S19) together with the differentiation of EGFPPOS CSCs-
ECCs in the early stages of myocardial restoration. In the
absence of GFs, CSCs-ECCs within the infarct died rapidly,
whereas the presence of GFs promoted their survival and
replication. Moreover, a time-dependent increase in the num-
ber of c-kitPOS , MDR1POS, and Sca-1POS cells undergoing the
transition from undifferentiated cells to small myocytes was
detected. At 1 day, EGFPPOS cells expressed stem cell
antigens and MEF2C, but sarcomeric proteins were absent.
At 2 days, cells were positive for sarcomeric myosin and at 3
to 4 days had developed into small EGFPPOS myocytes.
Connexin 43 and N-cadherin were present (Figure 5A and
5B). These cells, clustered in patches throughout the infarct,
increased with time (Figure 5C). At 1 to 2 days, new
arterioles had thick walls and ill-defined lumen. At 3 to 4
days, arterioles and capillaries increased; they were formed
by EGFPPOS and EGFPNEG cells (supplemental Figure S20).
GFs and Infarct Size
Myocardial infarction rates in GF-treated hearts at 16 days
and 4 months were 67% and 63%, respectively. Correspond-
ing values in untreated mice were 42% and 43%. Thus, infarct
size was 60% and 47% larger in GF-treated than in untreated
mice at the early and late time point, respectively (supple-
mental Figure S21). This unexpected result was the conse-
quence of a rapid regeneration of dead myocardium induced
by GFs, which rescued animals with extremely large infarcts
acutely after coronary occlusion. Figure 6A illustrates a 44%
infarct, a nearly maximum infarct size compatible with
survival in untreated mice at 16 days. The infarct corresponds
to a loss of 1.6 million myocytes from a total of 3.6 million.
GF-treated mice survived infarcts of 82% (Figure 6B) and
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86%; this is a striking result, as 2.9 and 3.1 million myocytes
were lost, respectively.
The group of untreated infarcted mice consisted of 123
animals (supplemental Table S1). The 87 animals that died 10
hours to 15 days after surgery had infarctions of 57% to 82%.
Twenty-two of the remaining 36 were euthanized at 16 days,
and 15 were studied functionally and structurally. The group
of GF-treated infarcted mice consisted of 107 animals. The 46
animals that died 10 hours to 15 days after surgery had
infarctions of 63% to 79%. Forty-nine of the remaining 61
were euthanized at 16 days, and 26 were studied. None of
untreated mice survived 16 days with infarcts larger than
60%. Conversely, 14 of 22 mice in the GF-treated group
survived 16 days with infarcts greater than 60%, and 7 had
75% to 86% infarcts. Of the remaining 14 untreated infarcted
mice, 10 survived 4 months and only 1 had an infarct that
reached 50%. Of the remaining 12 GF-treated infarcted
animals, 10 survived 4 months, and 6 had infarcts greater than
60% (Figure 6C; 68%). Thus, GF-treatment saved mice with
infarcts that are typically fatal.
Myocardial Regeneration
Four of 26 GF-treated mice euthanized at 16 days did not
respond to GF administration; they were undistinguishable
from untreated infarcted mice. Most likely, they were not
properly injected with GFs. Similarly, 2 of 10 GF-treated
mice at 4 months had no regenerating band. Thus, successful
treatment was obtained in 85% and 80% of treated mice.
Unsuccessfully treated mice were characterized structurally
(supplemental Table S2).
In untreated mice, the infarcts consisted of collagen type I
and III (Figure 6A). In treated mice, the regenerated myocar-
dium occupied 658% and 737% of the infarct at 16 days
(Figure 6B) and 4 months (Figure 6C), respectively. The new
band of myocardium was located in the mid-portion of the
wall and, in some cases, replaced the entire wall thickness
Figure 2. GF administration
and CSCs-ECCs. A through C,
Fluorescein-labeled HGF is
higher at the border zone (BZ)
and lower at the AV groove at
10 (A), 30 (B), and 60 (C) min-
utes after injection. RP indi-
cates rhodamine particles. D,
HGF-concentration is higher at
BZ, intermediate half-way (mid-
LV), and lower at atria.
*P0.05, ** P0.01 versus BZ
and mid-LV. E, Phosphorylat-
ed-substrates in CSCs-ECCs
of GF-treated infarcted hearts
(MI-T) increased 5-fold at 12
, 24, and 72 hours. F, Density-
plots (upper panels) of c-kitPOS
phospho-c-MetPOS cells in MI-T
at 24 hours. Dot-plots (lower
panels) of c-kit-phospho-c-Met
colocalization including c-kit-
negative cells (left) and exclud-
ing c-kit-negative cells (right).
G, Density-plot, Lewis lung
carcinoma cells (phospho-c-
Met). H, Phospho-c-Met, Lewis
lung carcinoma cells.
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(Figure 6B and 6C). At 16 days, the new myocardium
recovered 15% of the infarct, decreasing the infarct size from
67% to 57%. At 4 months, the formed myocardium accounted
for 54% of the infarct, reducing infarct size from 63% to 29%
(supplemental Figure S22).
The regenerated myocardium was composed of myocytes and
coronary vessels. At 16 days, myocytes varied in volume from
600 to 7200 m3 and at 4 months, from 700 to 20 000 m3
(Figure 6D). At both intervals, treated hearts generated an
average 3.2 million myocytes to compensate for a loss of 2.2
million. There were 4313 arterioles and 15548 capillaries/
mm2 at 16 days, and 316 arterioles and 39056 capillaries at
4 months. For comparison, there are 10 arterioles and 3500
capillaries/mm2 in myocardium in the adult heart. New vessels
contained erythrocytes (supplemental Figure S23).
To document that cells in the band were formed after infarction,
mice were exposed to BrdU; 849% and 943% myocytes and
vessels in the band were BrdUPOS at 16 days and 4 months,
respectively (Figure 6E and 6F; supplemental Figure S23). At 4
months, the spared myocardium adjacent to and distant from the
infarct had 176% and 83% BrdUPOS myocyte nuclei, respec-
tively (supplemental Figure S24). New myocytes were smaller than
adult myocytes (21 8002200 m3) but expressed nestin, desmin,
myosin, -sarcomeric actin, N-cadherin, and connexin 43 (supple-
mental Figure S25). These results indicate that, in response to HGF
and IGF-1, CSCs-ECCs translocate, grow, and differentiate, result-
ing in significant myocardial regeneration. A single GF had a
smaller impact, however, and the 2 GFs acted synergistically in
cardiac repair (supplemental Figure S26).
Myocyte Mechanics and Cell Fusion
Myocytes were isolated from regenerated and spared myo-
cardium (Figure 7A through 7F) of GF-treated hearts at 16
days, and their contractile behavior was determined. New
cells were smaller than old cells, had BrdUPOS nuclei, and
resembled neonatal myocytes. Connexin 43 and N-cadherin
were detected (Figure 7C through 7F). In comparison with
surviving myocytes, new cells exhibited higher peak short-
ening and velocity of shortening and relengthening (Figure
7G; supplemental Figure S27).
Figure 3. GFs mediate migration of
EGFPPOS cells. A through E, Heart per-
fused with Tyrode-solution. Two-photon
microscopy images at the BZ 15 hours
after infarct and 10 hours after GF
administration. Images of the same field
were taken 20 minutes apart (A, base-
line; B, 20 minutes; C, 40 minutes; D, 60
minutes; E, 80 minutes). EGFPPOS cells
(green, arrowheads) moved in the direc-
tion of large open arrows in 80 minutes.
White circles (A) surround EGFPPOS cells,
which were in the field and then progres-
sively disappeared (C, D, and E). Yellow
circle surrounds EGFPPOS cells, which
appear in D and are in field E. E through
G, Rectangles and a yellow circle sur-
round EGFPPOS cells detected by
2-photon microscopy (E; green) and con-
focal microscopy (F; green). Green-fluo-
rescence identifies the same EGFPPOS
cells (E and F). F, White-fluorescence
corresponds to hairpin-1POS apoptotic
myocyte-nuclei; EGFPPOS cells within the
infarct are viable (hairpin-1NEG). Myocytes
are cardiac myosin, red. G, EGFPPOS
cells express c-kit-MDR1 (magenta;
arrowheads).
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The discrepancy in size between old and new myocytes
makes it unlikely that fusion1,14 of the activated CSCs with
spared myocytes was implicated in the differentiation of these
cells into myocytes. Moreover, to rule out fusion of CSCs
with other cells, the number of X chromosomes was evalu-
ated in the regenerated myocytes of the female infarcted
treated mice. At most, 2 X chromosomes were detected in the
nuclei, strongly arguing against cell fusion (Figure 7H).
Cycling and noncycling new and old myocytes were identi-
fied by Ki67, and DNA content was measured in individual
nuclei. Mouse lymphocytes were used as control. Nuclei of
noncycling myocytes and lymphocytes had 2C DNA content,
whereas Ki67POS nuclei had DNA content intermediately
between diploid and tetraploid excluding cell fusion (supple-
mental Figure S28).
Cardiac Performance and Survival
Contraction in the infarct of GF-treated mice reappeared at 15
days and improved at 1, 3, and 4 -months (Figure 8A through
8E). Hemodynamics improved in GF-treated mice and dete-
riorated in untreated mice (Figure 8F). In GF-treated hearts,
from 16 days to 4 months, left ventricular end-diastolic
pressure decreased and LV-developed pressure and dP/dt
increased. Also, chamber volume decreased, attenuating dia-
stolic stress (Figure 8F). Together, these variables were
responsible for a 34% decrease in animal mortality (Figure
8G), despite 50% larger infarcts in GF-treated animals.
Thus, activation of CSCs-ECCs acutely after infarction elicits
a sustained regenerative response that ameliorates the anato-
my and function of the heart, improving animal survival.
Discussion
The results of the current study demonstrate that the mam-
malian heart contains a population of resident stem cells and
progenitor cells that, after activation, can migrate and invade
the infarcted myocardium, leading to a significant reconsti-
tution of the damaged portion of the wall and a remarkable
recovery of ventricular function. Myocardial regeneration
comprises parenchymal cells and coronary vessels, providing
additional evidence in support of the notion that the adult
heart possesses an extraordinary growth reserve capable of
restoring losses of tissue commonly considered fatal in
animals and humans. Commitment of cardiac primitive cells
to the myocyte lineage, together with the creation of small
actively dividing amplifying myocytes, occurs in the acute
phases of cardiac repair, whereas maturation and hypertrophy
of the newly formed cells constitute the predominant mech-
anisms of myocardial regeneration long-term after infarction.
Coronary arterioles and capillary structures are produced
concurrently with myocytes to ensure adequate oxygenation
of the developing myocardium. Differentiation and enlarge-
ment of myocytes is paralleled by expansion of the coronary
vasculature and microvasculature that tends to preserve blood
supply and oxygen diffusion to the surrounding cells. Ulti-
mately, the infarcted heart largely regains its anatomical
configuration, dramatically reversing ventricular dilation and
thinning of the wall. Although the normal architecture and
orientation of myocyte bundles across the wall was not
acquired, our findings suggest that local administration of
GFs may become a novel powerful therapeutic strategy for
the acutely decompensated infarcted heart.
CSCs-ECCs in the Adult Heart
The fact that the heart possesses a stem cell compartment has
been shown in several species,1–4,15,16 including large ani-
mals17 and humans.6,7,18 With one exception,16 these cells
have been characterized by the expression of the ypical stem
cell antigens c-kit, MDR1 or Sca-1. However, the fact that
cardiac primitive cells are self-renewing, clonogenic, and
multipotent, which are the critical variables for the definition
of a stem cell, has been documented only in rats1 and dogs.17
Because of this inevitable premise, it is difficult to reconcile
the claim made and terminology used when cells already
committed to the myocyte lineage and without established
epitopes have been interpreted as a novel class of cardiac
Figure 4. Migration of EGFPPOS cells. A through C, Two-photon
microscopy images of BZ fter perfusion with rhodamine-labeled
dextran (red), 5 hours after infarction, and immediately after GF
administration. Images were taken 20 minutes apart (A, base-
line; B, 20 minutes; C, 40 minutes). EGFPPOS cells (green; arrow-
heads) moved in the direction of large open arrows and in 40
minutes were outside of coronary vessels. D, EGFPPOS cells
detected by 2-photon microscopy (C, square) and confocal
microscopy. Green-fluorescence identifies the same EGFPPOS
cells (C and D, arrows). D, EGFPPOS cells express c-kit (white;
arrows). Myocytes indicate cardia -myosin, red. E, EGFPPOS cells
(arrowheads) within fibronectin-tunnels. Large open arrow indi-
cates the direction of moving cells.
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stem cells.16 Importantly, the majority of CSCs in dogs,17
humans,7 and here in the mouse heart expresses together
c-kit, MDR1, and Sca-1–like proteins. Additionally, these
stem cell antigens are not associated with a significant
difference in the ability of these primitive cells to acquire the
myocyte, endothelial, and smooth muscle cell lineage in
vitro17 and in vivo.7,17 The latter has been confirmed in the
mouse heart. The ability of clonogenic c-kitPOS cells to create
myocardial cells in vitro, however, is several-fold greater
than cells expressing MDR1, Sca-1–like protein. or c-kit,
MDR1. and Sca-1 together.17 Whether this in vitro property
of c-kitPOS cells has a comparable in vivo counterpart remains
an unanswered question.
The Infarcted Heart
Post-infarction cardiomyopathy is the major cause of heart
failure, and the current observations offer new insights concern-
ing the onset and evolution of this disease. On the basis of the
present results, the progressive nature of ischemic cardiomyop-
athy appears to be dictated by the inability of CSCs-ECCs to
translocate and home to the infarcted myocardium rather than by
limitations in the growth reserve of the damaged heart. The
resident stem cells distributed in the infarcted region do not
survive the ischemic event and die by apoptosis and necrosis in
a manner identical to that of myocytes and coronary vessels.
CSCs-ECCs are not capable of opposing the death signals
activated by permanent coronary occlusion and initiate regener-
ative growth within the infarcted myocardium. Moreover, these
primitive cells cannot escape replicative senescence with severe
telomeric shortening and activation of the death program in
end-stage failure7 or premature myocardial aging19 in humans.
Spontaneous myocardial regeneration within acute infarcts,
however, appears to be mediated by CSCS-ECCs, which un-
dergo lineage commitment and differentiation.7 With some
exceptions,7 tissue growth does not invade and replace the
infarcted myocardium but is restricted to the noninfarcted
portion of the ventricular wall.20 This is not a peculiar limitation
of the heart. Stem cells are efficient in maintaining organ
homeostasis but do not prevent the formation of a scar after
artery occlusion in the intestine, skin, brain, liver, kidney, and
the bone marrow.21,22
Consistent with previous observations of cardiac repair,1,5,17
early myocardial regeneration is characterized by the formation
of immature parenchymal cells and coronary vessels that resem-
ble the fetal heart. Cardiomyocytes, resistance arterioles, and
capillary structures mature with time, but only 20% of myo-
cytes reach the adult phenotype and have a volume of 10 000 to
20 000 m3 4 months after successful treatment (Figure 6D).
This is at variance with the process of postnatal development, as
myocytes acquire adult characteristics at 3 to 4 weeks after birth.
Interestingly, scattered regeneration of myocytes in the surviving
myocardium after infarction results in the formation of paren-
chymal cells that are indistinguishable from the preexisting
partners.5 This observation has led to the conclusion that contact
with differentiated cells and paracrine factors may be implicated
in the destiny of lineage-committed CSCs-ECCs.
On the basis of the belief that the heart lacks endogenous
regenerative capacity, early strategies of cardiac repair have used
the colonization of the myocardium with exogenous cells.23 The
presence of CSCs raises the unique prospect of reconstituting
dead myocardium after infarction, repopulating the hypertrophic
decompensated heart with new, better-functioning cells and
vascular structures, and, perhaps, restoring the physiological and
anatomical characteristics of the normal heart. These possibili-
ties have formed the basis of a new paradigm in which the heart
is viewed as a dynamic organ that constantly renews its cell
populations and has the inherent ability to reconstitute tissue.
Understanding cardiac homeostasis would offer the extraordi-
nary opportunity to potentiate this naturally occurring process
and promote myocardial repair after injury.24
Rescue of the Infarcted Heart
So far, experimental studies and clinical trials have used
rather heterogeneous bone marrow cell populations to regen-
Figure 5. Differentiation of EGFPPOS cells.
A and B, MI-T at 2 (A) and 4 (B) days.
EGFPPOS cells (green; arrows), positive
(A; magenta) or negative (B) for MDR1
are present within the infarct. Area
defined by a rectangle (A and B) is
shown at higher magnification in the
inset, cells express MEF2C (A and B;
white), cardiac myosin (A and B; red),
and connexin-43 (B; yellow). Small-
myocytes (A and B, arrowheads) are
present. In B, laminin appears bright
blue. Large myocytes without nuclei
reflect dead cells. C, ECCs expressing
MEF2C or MEF2C and cardiac myosin
increases with time. *P0.05, ** P0.001
versus 1 and 2 days.
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erate infarcted myocardium and have consistently shown an
improvement in function of the infarcted heart.23 However,
the most logical and potentially powerful cell to be uses is the
CSC. It is intuitively apparent that if the adult heart possesses
a pool of primitive multipotent cells, these cells have to be
tested first before more complex and unknown cells are
explored. The attraction of this approach is its simplicity.
Cells from other organs are not programmed to give rise to
Figure 6. Myocardial regeneration. A through C, Untreated MI (A) and MI-Ts at 16 days (B) and 4 months (C). Arrows show infarcted
nonregenerated (A) and infarcted regenerated (B and C) myocardium. BrdUPOS nuclei (A, fibroblasts). B and C, Four levels of regenera-
tion from base to apex. Groups of 3 panels show areas within rectangles. Each triplet illustrates myocytes (cardiac myosin, red),
collagen-type-I/type-III (blue), nuclei (PI, green), and BrdUPOS nuclei (white). BrdU labeling in regenerated-myocardium (B and C) indi-
cates that cells were formed after infarction. D, Myocyte size distribution. E and F, New myocytes (cardiac-myosin, red) in GF-treated
infarcted mice at 16 days (E) and 4 months (F). BrdUPOS-nuclei appear as white dots; laminin appears green.
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cardiomyocytes and coronary vessels, and transdifferentiation
requires nuclear reprogramming with chromatin reorganiza-
tion. This is a time-consuming process25 that delays the
formation of alternate progeny, affecting the onset and
efficiency of myocardial regeneration. Conversely, the in-
tramyocardial injection of GFs promotes the translocation of
CSCs-ECCs to the damaged area and activates their growth
and differentiation, resulting in the formation of functionally
competent myocardium. The blunted response to HGF or
IGF-1 emphasizes the need for a dual stimulation of CSCs-
ECCs: The survival and growth provided by IGF-1 together
with the chemotactic effects of HGF. The presence of small
new myocytes within the infarct at 1 to 2 days after coronary
ligation demonstrates that tissue reconstitution is an immedi-
Figure 7. Regenerated myocytes and cell fusion. A and B, Regenerated
(A) and spared (B) myocytes from MI-T. BrdUPOS nuclei are bright blue.
C-F, Connexin 43 (C and D, yellow) and N-cadherin (E and F, white).
BrdUPOS nuclei (C and E, green; D and F, bright blue). G, Sarcomere
mechanics from new and spared myocytes from GF-treated infarcted
hearts at 16 days. Tracings show the changes in length of sarcomeres.
H, Only 1 or 2 X chromosomes were detected (white dots).
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ate reaction that restores an amount of myocardium larger
than any other reported so far in the long term.
At variance with previous strategies,23 local GF administra-
tion benefited animals with infarcts that are typically fatal.
However, these results leave unanswered the question of why
ischemia does not activate stem cells locally, favoring their
homing to the damaged area, or whether the effects of GFs on
ischemic myocytes influenced cell viability. Myocardial ische-
mia is a potent inducer of IGF-126 and HGF.27 The injection of
GFs did not increase the number of bone marrow progenitor
cells in the circulation, as shown by the lack of changes in the
pool of CD45 and c-kitPOS cells in the peripheral blood (supple-
mental Figure S29); 240 g of HGF over a period of 12 days
was required to produce a modest increase in circulating
BMPCs.28 This quantity is 170 000-fold higher than the 1.4 ng
given here at a single time point (limitations; online).
Cell Migration
The locomotion of CSCs-ECCs occurs through the myocar-
dial interstitium independently from the coronary circulation.
CSCs-ECCs traverse in vitro a 3-dimensional substrate of
Matrigel and in vivo dense barriers of collagen type I and III.
MMP-2 and MMP-9 appear to be the proteolytic enzymes
responsible for the invasive phenotype of CSCs-ECCs and
their trafficking across the myocardial interstitium. However,
MMP-9 may trigger the release of stem cell factor29 from
CSCs-ECCs, although stem cell factor has no effects on the
invasive properties of these cells in vitro.17
The migratory elements of CSCs-ECCs may include mo-
togenic factors, and ischemia is a potent inducer of the chemoat-
tractants HGF, stromal cell-derived factor-1, and vascular endo-
thelial growth factor. Although these cytokines may favor cell
movement, it is only with HGF that waves of CSCs-ECCs are
engaged in a directional migration toward the injured myocar-
dium. A stop signal may also be present to promote the
accumulation of cells within the infarct. This involves the
extracellular substrates used by the cells to traverse the intersti-
tium. The ability of CSCs-ECCs to degrade extracellular matrix
provides a basis for the tunnel tracks found in the myocardium.
CSCs-ECCs adhere to the wall of fibronectin that delimit the
interstitial channels. Importantly, fibronectin is implicated in the
migration of c-kitPOS cells.30 Finally, the directional locomotion
Figure 8. Cardiac function and
mortality. A through E, Echocar-
diography of a noninfarcted-SO
(A), untreated infarcted heart at
4 months (B), and GF-treated
infarcted hearts at 15 days (C),
1 month (D), and 4 months (E).
Contraction in the infarcted
region is apparent in GF-treated
mice at 15 days and thereafter
(arrowheads). F, Functional
properties of SO, untreated MI
and MI-T. *, **, †P0.05 to 0.001
versus SO (*), MI (**) and MI-T
at 16 days (†). G, Mortality after
infarction was reduced in
GF-treated mice (P0.0001;
log-rank test) although these
mice had 50% larger infarcts.
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of cells is regulated by guidance factors. Ligand-receptor sys-
tems are potential candidates for defining the trajectory of
migrating CSCs-ECCs and, in our conditions, the activation of
c-Met by HGF may be the determinant element. MMPs, together
with the HGF-mediated changes in integrin phenotype of CSCs-
ECCs (A.L., unpublished data), may be crucial for effective
translocation of cells. Other systems, including the c-Met-related
family of semaphorins and neuropilins, are likely to be involved.
The long journey of a stem cell toward its final destination,
however, remains an intriguing and mysterious event.
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